30 results about "Lid margin" patented technology

An eyelid margin wipe comprising chemical means for adjusting the temperature of the wipe relative to the ambient temperature. The wipe is particularly useful for treatment of disorders of the eyelid or eyelid margin such as meibomian gland dysfunction.

A jojoba formulation has been developed for administration to the meibomian gland, for treatment of the symptoms of dry eye, and / or for drug delivery to the meibomian gland. The formulation incorporates the natural product jojoba wax, or components thereof, to enhance the spreading of the artificial tear as well as stabilize the tear film. The jojoba wax tear relieves irritation and discomfort as well as sharpens the blurred vision. Jojoba, because of its close chemical and physical properties to meibomian gland secretions, is effective upon topical application to penetrate the lid margin to reach the gland tissues where it may exert a therapeutic effect with or without an adjunctive agent.

The present invention provides a mucoadhesive broad spectrum antibiotic with anti-inflammatory characteristics with strong tissue penetration for improving lid margin function and the treatment of diseases associated therewith. The present invention further provides compositions and methods for treating and / or preventing the signs and / or symptoms of blepharitis and dry eye disease.

A jojoba formulation has been developed for administration to the meibomian gland, for treatment of the symptoms of dry eye, and / or for drug delivery to the meibomian gland. The formulation incorporates the natural product jojoba wax, or components thereof, to enhance the spreading of the artificial tear as well as stabilize the tear film. The jojoba wax tear relieves irritation and discomfort as well as sharpens the blurred vision. Jojoba, because of its close chemical and physical properties to meibomian gland secretions, is effective upon topical application to penetrate the lid margin to reach the gland tissues where it may exert a therapeutic effect with or without an adjunctive agent.

A jojoba formulation has been developed for administration to the meibomian gland, for treatment of the symptoms of dry eye, and / or for drug delivery to the meibomian gland. The formulation incorporates the natural product jojoba wax, or components thereof, to enhance the spreading of the artificial tear as well as stabilize the tear film. The jojoba wax tear relieves irritation and discomfort as well as sharpens the blurred vision. Jojoba, because of its close chemical and physical properties to meibomian gland secretions, is effective upon topical application to penetrate the lid margin to reach the gland tissues where it may exert a therapeutic effect with or without an adjunctive agent.

Methods and apparatuses are disclosed for the diagnosis and removal of the devitalized and / or dead cell material formed in the lid margin to attempt to restore a normal lid margin. In this manner, the devitalized and / or dead cell material are removed or the amount present is reduced or no longer present to prevent, reduce, or affect the transport of lipid secreted by the meibomian glands to the tear film to reduce evaporative dry eye and improve dry eye conditions in patients. The diagnosis and removal of devitalized and / or dead cell material may be performed at desired intervals. Patients that suffer from conditions that block meibomian gland orifices, partial, infrequent, or inhibited blinking resulting in reduced lipid secretions from meibomian glands, and / or blockages in meibomian gland channels reducing secretion of lipids through the meibomian gland orifices may require more frequent diagnosis and treatment to remove devitalized and / or dead cell material.

The invention discloses an eyelid positioning method based on strong direction weighted edge detection and RNL goodness of fit. An existing straight line fitting positioning method is high in positioning speed but low in positioning precision. The parabola fitting positioning method is high in fitting positioning precision, but low in positioning speed. The method comprises the following steps: segmenting upper and lower eyelids according to an iris circle center position, and determining upper and lower eyelid areas; secondly, preprocessing an image before eyelid detection by using a strong direction weighted edge-preserving denoising smoothing filtering operator; secondly, suppressing eyelash interference by using a strong direction weighted edge detection operator, and dynamically selecting edge detection operator parameters according to gray scale contrast values of regions above and below the eyelid edge in the iris image to obtain candidate eyelid edges to be fitted; and finally,fitting eyelid edges by adopting a least square method parabola, and screening eyelid edge selection points by taking RNL goodness of fit as an index to finish eyelid positioning. The method has goodrobustness, and an ideal positioning result can be obtained even for an upper eyelid which is shielded by eyelashes.

Disclosed herein are pharmaceutical compositions and methods for the treatment of anterior blepharitis and posterior blepharitis which may be of primary origin and not secondary to other factors such as infections, infestations or rosacea. The composition comprises Ivermectin in the range of about 0.001% to 20% by weight of the total composition. Topical administration of said compositions precisely to the eyelid margin provides therapeutic benefit to patients suffering from anterior blepharitis and posterior blepharitis.

Methods and apparatuses are disclosed for the diagnosis and removal of the devitalized and / or dead cell material formed in the lid margin to attempt to restore a normal lid margin. In this manner, the devitalized and / or dead cell material are removed or the amount present is reduced or no longer present to prevent, reduce, or affect the transport of lipid secreted by the meibomian glands to the tear film to reduce evaporative dry eye and improve dry eye conditions in patients. The diagnosis and removal of devitalized and / or dead cell material may be performed at desired intervals. Patients that suffer from conditions that block meibomian gland orifices, partial, infrequent, or inhibited blinking resulting in reduced lipid secretions from meibomian glands, and / or blockages in meibomian gland channels reducing secretion of lipids through the meibomian gland orifices may require more frequent diagnosis and treatment to remove devitalized and / or dead cell material.

Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and / or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and / or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

An eyelid speculum, a kit containing the eyelid speculum, and a method of using the eyelid speculum in the diagnosis and / or treatment of a patient are provided. The eyelid speculum includes a central ring having an upper surface, a lower surface, an inner side surface, an outer side surface, a first end, and a second end. The first end and the second end are separated by a gap, and the central ring defines an opening. The eyelid speculum also includes first and second eyelid margin holders that extend outwardly from the outer side surface of the central ring at the first end and second end, respectively, where each eyelid margin holder has an upper portion and a lower portion. In addition, the eyelid speculum includes finger tabs that extend upwardly from the upper portions of the first and second eyelid margin holders.

An ophthalmic measurement device and measurement system include a projection unit projecting an image on tear fluid accumulated at an edge of an eyelid and a surface of a cornea and conjunctiva; an imager takes a picture of the tear fluid accumulated at an edge of an eyelid and the surface of a cornea and conjunctiva; and a calculator determines a physical quantity of the tear fluid accumulated at an edge of an eyelid. The calculator acquires a physical quantity of a first reflection of the image projected on the tear fluid accumulated at an edge of an eyelid, and calculates a curvature radius of the surface of the tear fluid, from a distance between the projection unit and the surface of the tear fluid obtained by distance measurement, a physical quantity of the image, and the physical quantity of the first reflection.

Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and / or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

An eyelid speculum, a kit containing the eyelid speculum, and a method of using the eyelid speculum in the diagnosis and / or treatment of a patient are provided. The eyelid speculum includes a central ring having an upper surface, a lower surface, an inner side surface, an outer side surface, a first end, and a second end. The first end and the second end are separated by a gap, and the central ring defines an opening. The eyelid speculum also includes first and second eyelid margin holders that extend outwardly from the outer side surface of the central ring at the first end and second end, respectively, where each eyelid margin holder has an upper portion and a lower portion. In addition, the eyelid speculum includes finger tabs that extend upwardly from the upper portions of the first and second eyelid margin holders.

The invention provides eye lids margin illumination distance and levator palpebrae superior muscle strength measuring equipment. The equipment comprises a hook face fixing piece, a luminous element, a geisoma compressing piece and a pulling rod, wherein the hook face fixing piece is provided with at least one first through-hole, the pulling rod is connected to the geisoma compressing piece after being inserted into the first through-hole, and the light of the luminous element can form a liminescent printing point in the most protruding point of the cornea. The eye lids margin illumination distance and levator palpebrae superior muscle strength measuring equipment can perpendicularly fix the geisoma when levator palpebrae superior muscle strength is measured, and thus operation errors is reduced during measurement. An integrated measurement way makes a straightedge directly attach under the measuring device, the operator can directly read a corresponding number value, thus the operation time is shortened, the errors are further lowered, and precision of data is improved. Therefore, insufficient correction or overcorrection caused by insufficient ptotic amount judgment is avoided, and the surgery effect is improved. The whole standardized measuring tool can be fixed at the head of a patient, thus the operation is simpler and convenient, and the compatibility and the compliance of the patient are improved.

The present disclosure provides an ophthalmic formulation comprising one or more pharmaceutically acceptable excipients; a pharmaceutically active compound that is capable of reducing the amount or deleterious actions of autoantibodies on the ocular surface, such as IgG; In particular, the present disclosure provides an ophthalmic formulation where the pharmaceutically active compound is capable of treating a clinical condition selected from the group consisting of inflammatory, infectious and immunological ocular surface or intraocular disease that can cause symptoms of ocular discomfort, keratitis, dry eye disease, symblepheron formation, fornix foreshortening, eyelid margin / conjunctival keratinization, subconjunctival fibrosis, retinal gliosis and glaucoma.

A row of artificial eyelashes (10) to be secured to an eyelid edge having (i) a base (12) for securing to the eyelid edge and (ii) false eyelashes (14), the base (12) having first warp threads (16) woven by chain stitches forming stitches, the false eyelashes passing through the chain stitches rather than being tied to the chain stitches, and the base (12) having second warp threads (16) woven by chain stitches forming stitches. The base (12) has second warp threads (18) woven by chain stitches forming stitches through which the false eyelashes pass instead of being tied, the first warp threads (16) and the second warp threads (18) being interwoven, the false eyelashes (14) pass through the stitches of the base, in particular through the chained stitches of the first warps (16) and remain in the stitches of the base (12) rather than being tied on the stitches of the base (12).

The present invention relates to an improved process of manufacturing sterile topical ophthalmic aqueous nanosuspensions of nanocrystals of fluticasone propionate Form A. The sterile topical ophthalmic nanosuspensions are useful in the treatment of eye inflammation conditions such as blepharitis, posterior blepharitis, Meibomian gland dysfunction and dry eye through topical administration of said nanosuspensions to eyelids, eyelashes and eyelid margin.

A row (10) of artificial eyelashes to be secured to an eyelid edge, having (i) a base (12) for securing to the eyelid edge and (ii) false eyelashes (14), the base (12) having first warp threads (16) knitted by chain stitches, the false eyelashes (14) passing through the chain stitches rather than being tied thereto, where the base (12) has second warp threads (18) knitted by chain stitches, the second warp threads (18) passing through the chain stitches and the false eyelashes (14) passing through the chain stitches. The false eyelashes (14) pass through a chain stitch instead of being tied thereto, where the first warp threads (16) and the second warp threads (18) are interwoven.

The present invention is in the field of ocular disease therapy. In particular, the invention relates to a composition comprising pimecrolimus for use in the topical treatment of moderate to severe blepharitis, in particular in a patient group comprising subjects with a clinical diagnosis of moderate to severe blepharitis, wherein the subjects to be treated have signs and symptoms of moderate to severe blepharitis characterised by swelling of the eyelid margin, ocular debris and ocular discomfort. In particular, the present invention relates to an ophthalmic composition that shows a high patient acceptance and a clinically meaningful improvement in the signs and symptoms of treated patients.

The invention discloses an ophthalmologic combined set which comprises an eye pad and a treatment rod. Medicine liquid adsorbed by the eye pad comprises silver ion liquid and traditional Chinese medicine extract, concentration of silver ions in the medicine liquid is 2-8ppm, and active pharmaceutical ingredients of the traditional Chinese medicine extract include rose flower, chamomile, radix glycyrrhizae, folium mori, semen cassiae and fructus lycii; the treatment rod is a cotton swab with two ends closed by medical cotton, a pipe cavity of the treatment rod is filled with pure silver ion liquid of 5-10ppm, and one end of the cotton swab is a marking end which can be torn into two parts. When in use, after the marking end is torn into two parts, liquid enters the other medical cotton from top to bottom to wipe eyelash roots and eye lid margins. A combined formulation of silver ions and eyesight-improving traditional Chinese medicine bring effects of the silver ions and the eyesight-improving traditional Chinese medicine into play; by giving natural strong penetrability of the silver ions, treatment effect of traditional Chinese medicine ingredients is enhanced; a set mode combining the eye pad with the treatment rod is adopted, and the eye pad and the eye lid margin wiping substance treatment rod are separated for use, so that the ophthalmologic combined set is accurate in treatment and more safe and sanitary.

A row of artificial eyelashes and a method of making the same. A method for manufacturing a row of artificial eyelashes comprises at least the following two steps: (a) weaving an assembly (20) for forming a plurality of rows (10) of artificial eyelashes to be fixed to an eyelid edge, the assembly having at least two bases (12) for fixing to the eyelid edge, the bases being arranged parallel to and symmetrical to each other with respect to a median plane (P), and false eyelashes (14) arranged parallel to and symmetrical to each other with respect to the median plane (P); each base (12) has: first warp threads (16) knitted by chain stitches forming stitches through which false eyelashes (14) pass rather than are tied; the first warp threads (16) are woven by chain stitches forming stitches, and the second warp threads (18) are woven by chain stitches forming stitches, the false eyelashes (14) pass through the chain stitches instead of being tied thereon, the first warp threads (16) and the second warp threads (18) are interwoven, and (b) the false eyelashes (14) are woven by applying a mechanical load in the presence of an energy stimulus causing the material of the false eyelashes to heat, in particular by applying ultrasound or high frequency or by heating. And bending the artificial eyelashes and / or the base and / or the false eyelashes of the row (10).

A process of manufacturing sterile topical ophthalmic aqueous nanosuspensions of nanocrystals of fluticasone propionate Form A. The sterile topical ophthalmic nanosuspensions may be used in the treatment of eye inflammation conditions such as blepharitis, posterior blepharitis, Meibomian gland dysfunction and dry eye through topical administration of said nanosuspensions to eyelids, eyelashes and eyelid margin.

An eye treatment device for cleaning of eyelashes and eyelid margins in the treatment of an eye disease is provided. Said eye treatment device comprises a swab consisting of a treatment member and a substantially rigid rod, and a housing formed as a handle that accommodates a drive unit for moving the swab relative to the drive unit. The eye treatment device comprises heating means for heating the swab.

Disclosed herein are compositions and methods for eyelid cleansing and treatment of ocular conditions. The method of treating an ocular condition involves cleansing the eyelids with a first ophthalmic composition consisting essentially of water, PEG-80 sorbitan laurate, methylgluceth-20, PEG ‑120 Methyl Glucose Dioleate, Salicyl Phytosphingosine, Decyl Glucoside, 1,2‑Hexanediol, Caprylyl Glycol, Disodium Cocoamphodiacetate, Panthenol, Polyaminopropyl biguanide, sodium chloride, potassium chloride, and calcium chloride; and then applying a therapeutically effective amount of a second ophthalmic composition to the eyelid margin, wherein the second ophthalmic composition consists essentially of water and hypochlorous acid.

The present invention provides an ophthalmic formulation consisting essentially of one or more pharmaceutically acceptable excipients; a pharmaceutically active compound that is capable of reducing the amount of inflammatory neutrophil product on the ocular surface; and optionally a second pharmaceutically active compound selected from the group consisting of a steroid, an anti-inflammatory agent, a mucolytic agent and a combination thereof. In particular, the present invention provides an ophthalmic formulation where the pharmaceutically active compound is capable of treating a clinical condition selected from the group consisting of inflammatory and immunological ocular surface disease that can cause symptoms of ocular discomfort, mucocellular aggregates / debris in tear film, symblepheron formation, fornix foreshortening, eyelid margin / conjunctival keratinization, corneal neovascularization / pannus, subconjunctival fibrosis, and herpetic eye disease. The present invention also provides a method for diagnosing or monitoring an ocular surface disease.